Definitions

1. Donepezil was relatively well tolerated; adverse events were consistent with current labeling. (Web site)
2. Donepezil is generally better tolerated than others in its class, simpler to use, and the agent with the most number of well controlled clinical trials.
3. Donepezil is metabolized by CYP 450 isoenzymes 2D6 and 3A4 and undergoes glucuronidation. (Web site)
4. Donepezil was not clastogenic in the in vivo mouse micronucleus test and was not genotoxic in an in vivo unscheduled DNA synthesis assay in rats.
5. Donepezil was not mutagenic in the Ames reverse mutation assay in bacteria, or in a mouse lymphoma forward mutation assay in vitro.

Associated

1. Treatment with donepezil was sometimes associated with worse parkinsonism. (Web site)

Course

1. Currently, there is no definitive proof that use of donepezil or other similar agents alters the course or progression of Alzheimer's disease. (Web site)

Incidence

1. Donepezil did not significantly reduce the incidence of delirium. (Web site)

Improvement

1. However NPI scores showed less improvement in the donepezil group when compared to the placebo group. (Web site)

Vitamin

1. Combination therapy of donepezil and vitamin E in Alzheimer disease.

Studies

1. Recent studies suggest that Donepezil can improve speech in children with autism.

Comparison

1. Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo-controlled double-blind study. (Web site)

Individuals

1. In a secondary analyses, a subgroup of individuals with the Apolipoprotein E4 genotype showed sustained benefits with donepezil throughout the study. (Web site)

Effects

1. The effects of donepezil in Alzheimer's disease - results from a multinational trial. (Web site)

Trial

1. Therefore, if a patient chooses a trial of donepezil, the lower, 5-mg dose should be offered.

Agitation

1. Donepezil for the treatment of agitation in Alzheimer's disease. (Web site)

Dlb

1. A therapeutic efficacy of donepezil for DLB has recently been reported. (Web site)

Serious Adverse Events

1. Donepezil was well tolerated with no serious adverse events. (Web site)

Mild

1. The studies found that speech of austistic children who were mild to moderately affected appeared to improve from the use of Donepezil. (Web site)

Placebo

1. Withdrawal rates due to adverse events were low (placebo, 8.8%; donepezil 5 mg, 10.1%; 10 mg, 16.3%). (Web site)
2. FINDINGS: 95 patients assigned donepezil and 99 patients assigned placebo completed the study. (Web site)

Double-Blind Study

1. Donepezil hydrochloride: a double-blind study in autistic children Benazzi F (November 1999). (Web site)

Placebo Groups

1. At the end of the study, the difference in the mean K-MMSE scores between the donepezil and placebo groups approached statistical significance (p = 0.056). (Web site)

Aricept

1. Aricept (Donepezil, E2020) Treats symptoms of Alzheimer's disease such as confusion or memory loss.
2. Dementia. The cholinesterase inhibitor drugs donepezil (Aricept) and rivastigmine (Exelon) are used to treat Alzheimer's disease.
3. Burt et al (1999) reported on a small open trial of donepezil (Aricept) as an adjunctive treatment for acute manic and mixed states. (Web site)

Drugs

1. Many people with Pick disease cannot take one of these drugs, donepezil (Aricept), because the drug can worsen symptoms such as agitation and aggression. (Web site)
2. Aricept (Donepezil) is a member of a class of drugs known as acetylcholinesterase inhibitors.

Treatment

1. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period.
2. Vitamin E and donepezil for the treatment of mild cognitive impairment.
3. Donecept (Aricept, Donepezil) Used in the treatment of mild to moderate dementia in Alzheimer's patients.

Patients

1. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease.
2. Patients with past experience of donepezil (Aricept) therapy at the same study institution. (Web site)
3. More patients discontinued treatment because of adverse events in the donepezil group (n=20) than in the placebo group (n=8). (Web site)

Randomised

1. Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study. (Web site)

July 2002

1. In July 2002, a pilot study reported that donepezil improves the memory of aging pilots. (Web site)

Study

1. Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study.
2. Phase II study of donepezil in irradiated brain tumor patients: effect on cognitive function, mood, and quality of life. (Web site)
3. Most of the patients whose records were analyzed for the study had been prescribed donepezil. (Web site)

Cognition

1. These data indicate that donepezil is a well-tolerated drug that improves cognition and global function in patients with mild to moderate AD. (Web site)
2. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. (Web site)
3. INTERPRETATION: Donepezil improves cognition and preserves function in individuals with severe Alzheimer's disease who live in nursing homes. (Web site)

Efficacy

1. Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial. (Web site)
2. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. (Web site)
3. Its efficacy is similar to donepezil and tacrine. (Web site)

Randomized

1. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease.
2. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease [published correction appears in Neurology. (Web site)
3. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. (Web site)

Placebo-Controlled Study

1. Donepezil in vascular dementia: a randomized, placebo-controlled study.

Placebo-Controlled Trial

1. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. (Web site)
2. Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial. (Web site)
3. Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease.

Dementia

1. Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study. (Web site)
2. A comparison of the efficacy of donepezil in Parkinson's disease with dementia and dementia with Lewy bodies.
3. A patient with probable dementia with Lewy bodies, who showed improvement of dementia and parkinsonism by the administratim of donepezil. (Web site)

Alzheimer Disease

1. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. (Web site)
2. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease.
3. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study.

Galantamine

1. Comparative analysis of mortality in patients with Alzheimer's disease treated with donepezil or galantamine.
2. Dementia. Drugs used to treat Alzheimer's disease (donepezil, tacrine, galantamine) are also being investigated from this problem.

Rivastigmine

1. A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease.
2. Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease.
3. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease.

Donepezil

1. A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine.
2. Rivastigmine (Exelon) and donepezil (Aricept) may help manage dementia.
3. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology.

Categories

1. Alzheimer's Disease
2. Rivastigmine
3. Galantamine
4. Alzheimer Disease
5. Placebo-Controlled Trial
6. Books about "Donepezil" in Amazon.com
   

Continue: More Keywords - - - - - - - - - -